Cooperative Agreement UG1EY036344
Award Date 5/15/26
Completion Date 1/31/31
Dollars Obligated $493K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- Federal Grant Award Summary The University of California, San Francisco received a $984,000 Project Grant (R34 mechanism) from the National Eye Institute under the Vision Research program (CFDA 93.867) for a planning and feasibility study on decentralized clinical trial design for dry eye disease (DED). The award, effective September 30, 2025 through September 29, 2027, supports the development of a novel remote trial methodology that shifts DED research from traditional clinical settings into...
- Federal Grant Award Summary The University of California, San Francisco received a $900,600 Project Grant from the National Eye Institute under the Vision Research program (CFDA 93.867) effective September 1, 2025, through August 31, 2027. This award supports research to advance understanding of corneal limbal stem cells (LSCs) during wound healing, specifically investigating how injury impacts the limbal stem cell niche and the distinct roles of inner limbal stem cells (ILSCs) and outer...
- ADAPT Trial Cooperative Agreement Summary The National Eye Institute (NEI) awarded The Regents of the University of California, San Francisco a cooperative agreement valued at $1,662,447 (awarded May 1, 2026, with completion anticipated April 30, 2030) under the Vision Research program (CFDA 93.867) to conduct the Adalimumab Dose Adjustment for Pediatric Uveitis Treatment (ADAPT) Trial. This multicenter, randomized controlled trial will generate evidence-based dosing guidelines for adalimumab in...
- Federal Project Grant Award Summary The University of California, San Francisco received a $451,000 Project Grant from the National Eye Institute (Vision Research program, CFDA 93.867) to identify and characterize autoantibodies associated with Sjögren's disease, particularly as it manifests in dry eye disease (DED). The award period runs from April 1, 2026 through March 31, 2028. The primary research product is the application of Phage Immunoprecipitation Sequencing (PHIP-SEQ) technology to...
- Federal Cooperative Agreement Summary The National Eye Institute (NEI) awarded a $4.05 million Cooperative Agreement to the Northern California Institute for Research and Education, Inc. (NCIRE), effective August 1, 2025 through May 31, 2030, under the Vision Research program (CFDA 93.867). This award supports research to assess the prevalence and biological determinants of ocular post-acute sequelae of Ebola virus disease (PASE), which affects up to 34% of Ebola virus disease survivors. The...
- Federal Grant Award Summary The National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), awarded University of California, Davis a $719,012 Project Grant effective August 1, 2025, through July 31, 2030, to optimize suprachoroidal adeno-associated virus (AAV) delivery systems for retinal gene therapies in nonhuman primates. The research addresses significant limitations of conventional AAV administration routes by evaluating microcatheterization techniques and...
- Federal Cooperative Agreement Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Cooperative Agreement totaling $1,468,517 to The Regents of the University of California, San Francisco on August 4, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports the iSYNAPSE study, a multi-center, single-arm longitudinal clinical trial investigating early immunological markers that predict successful immunosuppression dose...
- Federal Project Grant Award Summary The National Eye Institute (NEI), under its Vision Research program (CFDA 93.867), awarded $902,000 to The Regents of the University of California, San Francisco for a two-year project (September 1, 2025–August 31, 2027) focused on multimodal characterization of a novel inherited mouse model of glaucoma. The research addresses the critical clinical need for neuroprotective therapeutic strategies for primary open-angle glaucoma (POAG), which affects over 80...
- Cooperative Agreement Summary The University of Rochester received a $744,451 Cooperative Agreement from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), awarded on March 17, 2026, with an ultimate completion date of February 28, 2027. This agreement funds the development of proteolysis-targeting chimeras (PROTACs)—small molecule compounds designed to inhibit secretory phospholipase A2-IIA (sPLA2-IIA)—as a novel therapeutic approach for age-related macular...
- Federal Grant Award Summary The University of California, San Diego received a $1.29M Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) to develop functionalized SARM1 nanobodies for glaucoma treatment. Awarded September 1, 2025, with completion targeted for May 31, 2028, this research initiative addresses the critical need for neuroprotective therapies to complement existing intraocular pressure-lowering treatments in glaucoma management. The...